I fail to understand why U.S. will be a tougher market. The only competitor for the Prescription Female Condoms in the U.S., FC2, produces in the U.S. itself. Cupid, producing in India, has a large margin to compete on price if required. FC2 itself recognises Cupid as a threat to their business (Evident from their Annual Reports and other releases).
I am on the fence about the IVD business. If they can achieve the targets provided, it will be a lucrative business. A lot depends on execution.
But agree on the comments about Management Sucession. The search for a good CEO or Sucessor to Mr. Garg has been nothing short of disappointing, especially with the intent of Mr. Garg wanting to sell his stake in the business becoming quite apparent.
| Subscribe To Our Free Newsletter |
